Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CG Oncology (CGON) Payables (2023 - 2025)

CG Oncology filings provide 3 years of Payables readings, the most recent being $5.7 million for Q4 2025.

  • On a quarterly basis, Payables fell 12.32% to $5.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was $5.7 million, a 12.32% decrease, with the full-year FY2025 number at $5.7 million, down 12.32% from a year prior.
  • Payables hit $5.7 million in Q4 2025 for CG Oncology, down from $9.2 million in the prior quarter.
  • In the past five years, Payables ranged from a high of $11.3 million in Q3 2024 to a low of $3.2 million in Q4 2023.
  • Median Payables over the past 3 years was $6.7 million (2025), compared with a mean of $6.9 million.
  • Biggest five-year swings in Payables: soared 101.02% in 2024 and later decreased 18.85% in 2025.
  • CG Oncology's Payables stood at $3.2 million in 2023, then soared by 101.02% to $6.5 million in 2024, then decreased by 12.32% to $5.7 million in 2025.
  • The last three reported values for Payables were $5.7 million (Q4 2025), $9.2 million (Q3 2025), and $7.1 million (Q2 2025) per Business Quant data.